Patient characteristics
| . | Patients with AML (n = 1001) . |
|---|---|
| Male:female ratio (M/F) | 539:462 |
| Median age, y (range) | 61 (1-93) |
| Age <65 y, n (%) | 597 (59.7) |
| Survival outcome available, n∗ (%) | 881 (92.4) |
| Treatment available,n∗ (%) | 870 (91.3) |
| Conventional chemotherapy | 688 (72.2) |
| Nonintensive therapy† | 144 (15.1) |
| Palliative care | 37 (3.9) |
| FLT3-inhibitors (alone or in combination with CTX) | 107 (11.2) |
| Hematopoietic stem cell transplantation | 323 (33.9) |
| . | Patients with AML (n = 1001) . |
|---|---|
| Male:female ratio (M/F) | 539:462 |
| Median age, y (range) | 61 (1-93) |
| Age <65 y, n (%) | 597 (59.7) |
| Survival outcome available, n∗ (%) | 881 (92.4) |
| Treatment available,n∗ (%) | 870 (91.3) |
| Conventional chemotherapy | 688 (72.2) |
| Nonintensive therapy† | 144 (15.1) |
| Palliative care | 37 (3.9) |
| FLT3-inhibitors (alone or in combination with CTX) | 107 (11.2) |
| Hematopoietic stem cell transplantation | 323 (33.9) |